Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sunvozertinib - Dizal Pharmaceuticals

Next Previous
Drug Profile

Sunvozertinib - Dizal Pharmaceuticals

Alternative Names: DZD-9008; Zegfrovy

Latest Information Update: 24 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dizal Pharmaceutical
  • Class Amides; Amines; Aniline compounds; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Phenyl ethers; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Non-small cell lung cancer

Most Recent Events

  • 19 Jun 2025 FDA assigns PDUFA action date of 07/07/2025 for sunvozertinib for Non-small cell lung cancer
  • 19 Jun 2025 Dizal Pharmaceutical completes enrolment in the phase III WU-KONG28 trial in Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in Turkey, Poland, Netherlands, Germany, Canada, Czech Republic, Brazil, Belgium, Austria, Argentina, Italy, Spain, USA, Australia, France and China (PO) (NCT05668988)
  • 20 Mar 2025 Efficacy and adverse events data from the phase-II WUKONG-32 trial in Non-small cell lung cancer released by Dizal Pharmaceutical

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top